Joe has been a Partner at Sofinnova Partners since 2020. Prior to this he was at Arix Bioscience plc, an LSE-listed venture capital firm where he was co-founder and CEO for 5 years. Joe has extensive experience in the healthcare and life science industries, including 12 years as partner at Abingworth LLP, where he led venture-style investments in public companies and the formation of the firm’s public equities fund.

‍

As an investor and active board member, he focuses on growth-stage life science companies. He has helped companies with financings, IPOs, and M&A, including Algeta (sold to Bayer for $2.9 billion), Amarin (listed on the Nasdaq), Autolus (listed on the Nasdaq) and Cytos (merged with Kuros).

‍

Joe started his career at the Wellcome Trust and became head of the strategy group for 9 years. He then moved into equities research as a pharmaceuticals analyst at Dresdner Kleinwort Benson, and then held a fund management role within First State Investments’ global healthcare & biotechnology fund, before moving into venture capital in 2004. He holds a PhD in Biochemistry.